openPR Logo
Press release

The XMD Project xenograft.org: A Centralized Resource for Preclinical In Vivo Cancer Models

08-27-2025 08:12 PM CET | Health & Medicine

Press release from: Getnews

/ PR Agency: Press Release Distributors
The XMD Project xenograft.org: A Centralized Resource

Image: https://www.globalnewslines.com/uploads/2025/08/1756267469.jpg

Plymouth Meeting, PA - August 27, 2025 - Cancer remains one of the greatest health burdens worldwide. Preclinical models are indispensable for developing therapies that can effectively translate from the laboratory to the clinic. The Xenograft Models Database [https://xenograft.org/] (XMD) project ensures that scientists have access to the best tools and the most comprehensive datasets available. Cancer research is driving the development of therapies that extend survival and improve quality of life for patients worldwide.

The cornerstone of this progress is rigorous preclinical research, which relies on in vivo models that faithfully reproduce the complexity of human tumors. To meet this demand, the xenograft.org [https://xenograft.org/] project has emerged as a central reference platform, designed to provide scientists and biotechnology innovators with access to a broad spectrum of xenograft and related oncology models.

The XMD project was launched in 2024 as a collaborative initiative, funded in part by a Cancer Research Institute data program grant. Its mission is to consolidate, standardize, and disseminate information about in vivo tumor models, ensuring that research groups and cancer centers have access to the most relevant resources. The database houses detailed information on a wide range of in vivo research preclinical systems, including xenograft models, syngeneic tumor models, patient-derived xenografts (PDX), cell line-derived xenografts (CDX), and immuno-oncology models.

XMD is unique in its dual structure: it integrates XMD-generated datasets with curated, aggregated data obtained from collaborators, oncology hospitals, and research centers worldwide. This hybrid model ensures both breadth and depth, offering an unparalleled reference point for investigators working across different cancer types and therapeutic modalities.

For cancer research laboratories, in vivo tumor models remain the most powerful tools to evaluate tumor growth, therapeutic efficacy, and resistance mechanisms prior to clinical translation. The XMD platform provides essential datasets that include:

* Tumor growth kinetics data for a wide range of xenograft models.
* Tumorigenicity profiles of cancer cell lines and their in vivo characteristics.
* Model availability and reference systems.

By consolidating these resources, xenograft.org [https://xenograft.org/] enables scientists to select the optimal oncology models for their preclinical studies, reducing redundancy, accelerating development timelines, and enhancing reproducibility across laboratories. XMD initiative is working on future integration of detailed genetic and pharmacologic characterization data to create a powerful platform for translational research. This integrative approach addresses one of the most pressing challenges in oncology: the translation of complex tumor genomics into practical clinical decision-making.

By linking preclinical data with genomic signatures, the XMD platform empowers researchers to design smarter experiments and enables pharmaceutical developers to de-risk drug pipelines before entering costly clinical phases. XMD provides a centralized hub for in vivo oncology models [https://xenograft.org/] that can serve the needs of academic scientists, industry researchers, and clinical investigators alike. The project's growth is supported by ongoing contributions from cancer research centers, biotechnology organizations, and hospitals that recognize the value of centralizing in vivo tumor model data.

XMD [https://xenograft.org/] | 3025 Chemical Road | Plymouth Meeting, PA | 19462 | info@xenograft.org
Media Contact
Company Name: Xenograft Models Database
Contact Person: Media Relations
Email: Send Email [http://www.universalpressrelease.com/?pr=the-xmd-project-xenograftorg-a-centralized-resource-for-preclinical-in-vivo-cancer-models]
Address:3025 Chemical Road
City: Plymouth Meeting
State: PA 19462
Country: United States
Website: http://xenograft.org/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The XMD Project xenograft.org: A Centralized Resource for Preclinical In Vivo Cancer Models here

News-ID: 4161131 • Views:

More Releases from Getnews

Dr Jeffrey Mathews Calls for Greater Awareness of Oral-Systemic Health Connection
Dr Jeffrey Mathews Calls for Greater Awareness of Oral-Systemic Health Connectio …
Feature interview highlights the growing link between oral health, confidence, and long-term wellbeing Dr Jeffrey Mathews, DDS, a leading cosmetic and family dentist based in Goodlettsville, Tennessee, is using the release of his new in-depth interview, In Conversation with Dr Jeffrey Mathews: The Future of Dentistry and Beyond, to raise awareness of the strong connection between oral health and overall systemic health. Drawing from his 15 years of clinical experience, Dr Mathews
Capodagli Property Company Unveils Plans for Upcoming Leasing at Meridia Bound Brook 300
Capodagli Property Company Unveils Plans for Upcoming Leasing at Meridia Bound B …
Image: https://www.globalnewslines.com/uploads/2025/12/1764950075.jpg Bound Brook 300 is a six-story, mixed-use residential development that will redefine urban living in Bound Brook. Linden, New Jersey - December 5, 2025 - The project will feature 60 thoughtfully designed residential units [http://capodagli.com/] plus one management unit, offering modern and comfortable living spaces for a diverse community. Residents will also enjoy convenient amenities, including 12 cage storage units, and 35 bike parking spaces. Meridia Bound Brook 300 will include
IABDM Announces 2026 Annual Conference:
IABDM Announces 2026 Annual Conference: "Biohacking in Dentistry" With Exclusive …
Apex, NC - The International Academy of Biological Dentistry and Medicine (IABDM) has announced its 2026 Annual Conference: Biohacking in Dentistry, a landmark event exploring how emerging biohacking tools, advanced diagnostics, and integrative health strategies are transforming modern biological dentistry. The conference will feature expert-led keynotes, hands-on sessions, and an Exhibitor Expo showcasing the latest technologies and holistic innovations. Attendees will also benefit from exclusive early bird pricing now available
Former LivePerson CEO Launches KID Registered , a Safe Creative AI Device Amid Alarming AI Toy Safety Findings.
Former LivePerson CEO Launches KID Registered , a Safe Creative AI Device Amid A …
Image: https://www.globalnewslines.com/uploads/2025/12/1764947497.jpg LOS ALTOS, Calif. - Dec 5, 2025 - KID Company [https://www.kidco.ai/] today announced the launch of KID Registered , a creative AI device built specifically for children ages 4 to 12. With no ads, no browsing, and no scrolling, KID offers families a safer alternative to screens optimized for attention. Parents maintain clear visibility and control through a transparent parent app -without surveillance. KID's design philosophy extends beyond software to

All 5 Releases